Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/emtricitabine in patients with toxicity attributable to didanosine

HIV Clinical Trials

Volumn 11, Issue 2, 2010, Pages 118-120

  Palacios, R ^a   Rivero, A ^b   Santos, I ^c   Rios M ^d   Castano M ^e   Del Arco, A ^f   Santos, J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e HOSPITAL COSTA DEL SOL   (Spain)

^f HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DIDANOSINE; EMTRICITABINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LAMIVUDINE; LOW DENSITY LIPOPROTEIN; TENOFOVIR; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ASTHENIA; BONE NECROSIS; CHOLESTEROL BLOOD LEVEL; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOLLOW UP; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; LETTER; LIPODYSTROPHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; NEPHROTOXICITY; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TREATMENT OUTCOME; XEROSTOMIA;

ADENINE; ANTI-HIV AGENTS; DEOXYCYTIDINE; DIDANOSINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FASTING; HIV INFECTIONS; HUMANS; LAMIVUDINE; LIPIDS; LIVER FUNCTION TESTS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953586742     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1102-118     Document Type: Letter

References (8)

1. Perry CM, Noble S. Didanosine: an updated review of its use in HIV infection. Drug. 1999;58:1099-1135. (Pubitemid 30055048)
2. Moreno S, Hernández E, Dronda F. Didanosine entericcoated capsule: current role in patients with HIV-1 infection. Drug. 2007;67:1441-1462.
3. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis. 2009;49: 626-635.
4. Gazzard BG, on behalf of the BHIVA Treatment Guidelines. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563-608.
5. Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodefi ciency virus infection (update February 2009). Panel de expertos Gesida y Plan Nacional del sida. Enferm Infecc Microbiol Clin. 2009;27:222-235.
6. Palacios R, Aguilar I, Hidalgo A, Santos J. Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naïve patients. Exp Rev Anti Infect Ther. 2006;4: 965-971.
7. Fisher M, Moyle GJ, Shahmanesh M, et al. Randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defi c Syndr. 2009;51:562-568.
8. DeJesus E, Pozniak A, Gallant J, et al. Improvement in fasting lipids but minimal recovery of limb fat were seen 96 weeks after switching from lamivudine/zidovudine plus efavirenz to fi xed-dose efavirenz/emtricitabine/ tenofovir DF in HIV-infected patients. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 12-15, 2009; San Francisco, CA USA. Poster Number H-1572.